Cargando…
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of S...
Autores principales: | Ye, Gang, Gallant, Joseph, Zheng, Jian, Massey, Christopher, Shi, Ke, Tai, Wanbo, Odle, Abby, Vickers, Molly, Shang, Jian, Wan, Yushun, Du, Lanying, Aihara, Hideki, Perlman, Stanley, LeBeau, Aaron, Li, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354634/ https://www.ncbi.nlm.nih.gov/pubmed/34338634 http://dx.doi.org/10.7554/eLife.64815 |
Ejemplares similares
-
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2
por: Ye, Gang, et al.
Publicado: (2020) -
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022) -
Vaccination in Kidney Transplant Candidates
por: Gajurel, Kiran, et al.
Publicado: (2023) -
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
por: Mast, Fred D, et al.
Publicado: (2021) -
Anti-candidal Effect of Ocimum sanctum: A Systematic Review on Microbial Studies
por: R, Chandini, et al.
Publicado: (2022)